Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Skin Metabolite, Farnesyl Pyrophosphate, Regulates Epidermal Response to Inflammation, Oxidative Stress, and Migration.

Pastar I, Stojadinovic O, Sawaya AP, Stone RC, Lindley LE, Ojeh N, Vukelic S, Samuels HH, Tomic-Canic M.

J Cell Physiol. 2016 Nov;231(11):2452-63. doi: 10.1002/jcp.25357. Epub 2016 Mar 9.

2.

Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain.

Das S, Yeung KT, Mahajan MA, Samuels HH.

BMC Cancer. 2014 Nov 20;14:852. doi: 10.1186/1471-2407-14-852.

3.

A novel cell lysis approach reveals that caspase-2 rapidly translocates from the nucleus to the cytoplasm in response to apoptotic stimuli.

Tinnikov AA, Samuels HH.

PLoS One. 2013 Apr 15;8(4):e61085. doi: 10.1371/journal.pone.0061085. Print 2013.

4.

Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation.

Yang YJ, Baltus AE, Mathew RS, Murphy EA, Evrony GD, Gonzalez DM, Wang EP, Marshall-Walker CA, Barry BJ, Murn J, Tatarakis A, Mahajan MA, Samuels HH, Shi Y, Golden JA, Mahajnah M, Shenhav R, Walsh CA.

Cell. 2012 Nov 21;151(5):1097-112. doi: 10.1016/j.cell.2012.10.043.

5.

A novel transcription complex that selectively modulates apoptosis of breast cancer cells through regulation of FASTKD2.

Yeung KT, Das S, Zhang J, Lomniczi A, Ojeda SR, Xu CF, Neubert TA, Samuels HH.

Mol Cell Biol. 2011 Jun;31(11):2287-98. doi: 10.1128/MCB.01381-10. Epub 2011 Mar 28.

6.

Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.

Goyanka R, Das S, Samuels HH, Cardozo T.

Protein Eng Des Sel. 2010 Nov;23(11):809-15. doi: 10.1093/protein/gzq056. Epub 2010 Sep 3.

7.

Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor.

Vukelic S, Stojadinovic O, Pastar I, Vouthounis C, Krzyzanowska A, Das S, Samuels HH, Tomic-Canic M.

J Biol Chem. 2010 Jan 15;285(3):1980-8. doi: 10.1074/jbc.M109.016741. Epub 2009 Nov 10.

8.

Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells.

Tinnikov AA, Yeung KT, Das S, Samuels HH.

Cancer Res. 2009 Feb 15;69(4):1375-82. doi: 10.1158/0008-5472.CAN-08-2896. Epub 2009 Feb 3.

9.

Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation.

Garapaty S, Xu CF, Trojer P, Mahajan MA, Neubert TA, Samuels HH.

J Biol Chem. 2009 Mar 20;284(12):7542-52. doi: 10.1074/jbc.M805872200. Epub 2009 Jan 8.

10.

Promoting breast health among women in the U.S. Virgin Islands: a focused study of the needs of Caribbean women.

Underwood S, Johnson ER, Callwood G, Evans EE, Matthew A, Scotland-Brooks C, Hanley C, Johnson-Harrigan D, LeFlore D, Williams D, Samuels H, Francis J, Arthur J, Clinkscales J, Joseph M, Heskey N, D'Abreau R, Fleming R, Penn S, Browne TA, Donastorg T, Scarbriel Y.

J Natl Black Nurses Assoc. 2007 Dec;18(2):53-62.

11.
12.

Components of the CCR4-NOT complex function as nuclear hormone receptor coactivators via association with the NRC-interacting Factor NIF-1.

Garapaty S, Mahajan MA, Samuels HH.

J Biol Chem. 2008 Mar 14;283(11):6806-16. doi: 10.1074/jbc.M706986200. Epub 2008 Jan 7.

13.

Farnesyl pyrophosphate is a novel transcriptional activator for a subset of nuclear hormone receptors.

Das S, Schapira M, Tomic-Canic M, Goyanka R, Cardozo T, Samuels HH.

Mol Endocrinol. 2007 Nov;21(11):2672-86. Epub 2007 Jul 31.

PMID:
17666588
15.

The nuclear receptor interacting factor-3 transcriptional coregulator mediates rapid apoptosis in breast cancer cells through direct and bystander-mediated events.

Das S, Nwachukwu JC, Li D, Vulin AI, Martinez-Caballero S, Kinnally KW, Samuels HH.

Cancer Res. 2007 Feb 15;67(4):1775-82. Erratum in: Cancer Res. 2007 May 1;67(9):4535.

16.

Direct identification of proteins from T47D cells and murine brain tissue by matrix-assisted laser desorption/ionization post-source decay/collision-induced dissociation.

Pevsner PH, Naftolin F, Hillman DE, Miller DC, Fadiel A, Kogus A, Stern A, Samuels HH.

Rapid Commun Mass Spectrom. 2007;21(3):429-36.

PMID:
17216666
17.

International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors.

Flamant F, Baxter JD, Forrest D, Refetoff S, Samuels H, Scanlan TS, Vennström B, Samarut J.

Pharmacol Rev. 2006 Dec;58(4):705-11. Review. No abstract available.

PMID:
17132849
18.

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.

Mathur M, Samuels HH.

Oncogene. 2007 Jan 11;26(2):277-83. Epub 2006 Jul 10.

PMID:
16832349
19.

The N-Terminal A/B domain of the thyroid hormone receptor-beta2 isoform influences ligand-dependent recruitment of coactivators to the ligand-binding domain.

Tian H, Mahajan MA, Wong CT, Habeos I, Samuels HH.

Mol Endocrinol. 2006 Sep;20(9):2036-51. Epub 2006 Apr 27.

PMID:
16645037
20.

Nuclear hormone receptor coregulator: role in hormone action, metabolism, growth, and development.

Mahajan MA, Samuels HH.

Endocr Rev. 2005 Jun;26(4):583-97. Epub 2004 Nov 23. Review.

PMID:
15561801
21.
22.
23.
24.

Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer.

Li D, Yamada T, Wang F, Vulin AI, Samuels HH.

J Biol Chem. 2004 Feb 27;279(9):7427-37. Epub 2003 Dec 10.

25.
26.

Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking.

Schapira M, Raaka BM, Das S, Fan L, Totrov M, Zhou Z, Wilson SR, Abagyan R, Samuels HH.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7354-9. Epub 2003 May 30.

27.

RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition.

Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, Juste D, Samuels HH.

Oncogene. 2002 Nov 7;21(51):7850-60.

29.
30.
31.

In silico discovery of novel retinoic acid receptor agonist structures.

Schapira M, Raaka BM, Samuels HH, Abagyan R.

BMC Struct Biol. 2001;1:1. Epub 2001 Jun 4.

32.
33.
34.

Rational discovery of novel nuclear hormone receptor antagonists.

Schapira M, Raaka BM, Samuels HH, Abagyan R.

Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1008-13.

35.

NRIF3 is a novel coactivator mediating functional specificity of nuclear hormone receptors.

Li D, Desai-Yajnik V, Lo E, Schapira M, Abagyan R, Samuels HH.

Mol Cell Biol. 1999 Oct;19(10):7191-202.

36.

Regulation of the mdm2 oncogene by thyroid hormone receptor.

Qi JS, Yuan Y, Desai-Yajnik V, Samuels HH.

Mol Cell Biol. 1999 Jan;19(1):864-72.

37.

Role of the conserved C-terminal region of thyroid hormone receptor-alpha in ligand-dependent transcriptional activation.

Selmi-Ruby S, Casanova J, Malhotra S, Roussett B, Raaka BM, Samuels HH.

Mol Cell Endocrinol. 1998 Mar 16;138(1-2):105-14.

PMID:
9685219
38.
39.

TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors.

Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH.

Mol Endocrinol. 1998 Jan;12(1):4-18.

PMID:
9440806
40.
41.
42.

Novel regulation of keratin gene expression by thyroid hormone and retinoid receptors.

Tomić-Canić M, Day D, Samuels HH, Freedberg IM, Blumenberg M.

J Biol Chem. 1996 Jan 19;271(3):1416-23.

43.
44.

Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator.

Desai-Yajnik V, Hadzic E, Modlinger P, Malhotra S, Gechlik G, Samuels HH.

J Virol. 1995 Aug;69(8):5103-12.

46.
47.

Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor.

Casanova J, Helmer E, Selmi-Ruby S, Qi JS, Au-Fliegner M, Desai-Yajnik V, Koudinova N, Yarm F, Raaka BM, Samuels HH.

Mol Cell Biol. 1994 Sep;14(9):5756-65.

48.

Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.

Hao E, Menke JB, Smith AM, Jones C, Geffner ME, Hershman JM, Wuerth JP, Samuels HH, Ways DK, Usala SJ.

Mol Endocrinol. 1994 Jul;8(7):841-51.

PMID:
7984146
49.

Supplemental Content

Loading ...
Support Center